Financials in USD. Standardized financial statements.
A compact view of how Rising BioSciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Revenue? | $782,280 | $163,734 |
| Revenue Growth? | +377.8% | 0.0% |
| Cost of Revenue? | $333,903 | $232,671 |
| Gross Profit? | $448,377 | -$68,937 |
| Gross Margin? | +57.3% | -42.1% |
| Operating Expenses? | $164,210 | $110,324 |
| Operating Income? | $284,170 | -$179,260 |
| EBITDA? | $152,687 | -$145,741 |
| Income Before Tax | $49,762 | -$253,233 |
| Income Tax Expense | $0 | $0 |
| Net Income? | $49,762 | -$253,233 |
| EPS? | $0.00 | $-0.00 |
| Diluted EPS? | $0.00 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality